| Beetroot (Beta vulgaris L.) — An edible root vegetable and functional food containing inorganic nitrate (NO3−), betalain pigments (primarily betanin and related betacyanins), betaxanthins, phenolic compounds, and betaine. Classified as a Food Source rather than an individual compound or standardized pharmaceutical agent. Common abbreviations include BR (beetroot) and BRJ (beetroot juice). Its most established biological action is the dietary nitrate–nitrite–nitric oxide pathway, which supports vascular NO availability. Betalains exhibit antioxidant, anti-inflammatory, and experimental anticancer activities. Whole beetroot, juice, concentrated nitrate shots, and extracts have different compositions and cannot be considered pharmacologically interchangeable. Anticancer activity remains preclinical.
Primary mechanisms (ranked):
- Dietary nitrate–nitrite–nitric oxide pathway: Oral bacterial nitrate reduction and subsequent nitrite-to-NO conversion increase NO bioavailability, activating soluble guanylate cyclase and cGMP signaling in vascular smooth muscle. This promotes vasodilation and can reduce systolic blood pressure.
- Betalain-mediated apoptosis: Betanin and betalain-rich extracts can increase Bax/Bcl-2 signaling ratios, activate caspases, and promote apoptosis in experimental cancer models (model-dependent).
- Cell-cycle and proliferation control: Betalain preparations can suppress cancer-cell proliferation and induce cell-cycle arrest, including G2/M arrest in selected models.
- Inflammatory signaling suppression: Betalains can inhibit NF-κB-associated signaling and reduce COX-2, iNOS, TNF-α, and IL-6 in experimental systems.
- Oxidative stress regulation: Betalains can reduce oxidative damage and support endogenous antioxidant defenses. Certain cancer-cell systems instead exhibit increased ROS associated with cytotoxicity (context-dependent).
- Mitochondrial apoptotic signaling: Changes in mitochondrial membrane potential and downstream caspase signaling have been observed with betalain treatment in selected cancer models.
- NRF2-associated antioxidant responses: Modulation of cellular antioxidant defense pathways is a possible secondary, context-dependent mechanism rather than a clinically established anticancer action.
Bioavailability / PK relevance: Dietary nitrate is absorbed efficiently and participates in enterosalivary recycling. Oral nitrate-reducing bacteria are important for nitrite production, and antibacterial mouthwash can substantially suppress this conversion. Plasma nitrate and related NO metabolites increase after consuming beetroot juice or whole beetroot. By contrast, systemic availability of intact betanin is poor; a human crossover study detected no plasma betanin after beetroot juice or whole-beet consumption. Betalain stability and exposure depend on processing, formulation, digestion, and metabolism.
In-vitro vs systemic exposure relevance: Most direct anticancer experiments use isolated betalains or concentrated extracts at exposure levels not demonstrated to be achievable in human tumors following ordinary beetroot consumption. Tested purified-betanin concentrations have commonly ranged from approximately 1 to 80 µM. Systemic exposure to intact betanin is generally much lower and may be undetectable. Anticancer results must therefore not be extrapolated directly to dietary servings. The nitrate–NO pathway is physiologically active at achievable oral dietary doses and is distinct from the high-concentration anticancer experiments.
Clinical evidence status: RCT and meta-analysis evidence supports modest systolic blood-pressure reduction from nitrate-rich beetroot juice, with low-to-moderate certainty depending on the analysis. Human exercise-performance evidence is mixed and dependent on training status, protocol, and outcome. Anticancer evidence is preclinical, consisting primarily of cell culture and animal studies of beetroot extracts or isolated betalains. No established clinical evidence demonstrates that consuming beetroot treats cancer or improves cancer survival. It is not an approved anticancer therapy.
Safety / clinical considerations: Beetroot is generally well tolerated as food. Concentrated nitrate products may add to blood-pressure-lowering effects in susceptible individuals. Beetroot contains oxalates, relevant to some patients with calcium-oxalate stone risk, and can cause harmless red or pink urine or stools (beeturia). Dietary nitrate content varies considerably with cultivar, cultivation, storage, and processing. These considerations are especially important when comparing whole beetroot with concentrated beetroot supplements.
Beetroot Mechanistic Effects
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Nitrate–Nitrite–NO–sGC–cGMP |
↔ / context-dependent |
↑ NO bioavailability; ↑ cGMP |
R |
Vasodilation and blood-pressure reduction |
Strongest clinically relevant mechanism. Requires enterosalivary nitrate conversion. Increased systemic NO availability does not establish anticancer activity; tumor NO effects are concentration- and context-dependent. |
| 2 |
Intrinsic and Extrinsic Apoptosis |
↑ Bax, BAD, Fas; ↓ Bcl-2; ↑ caspases |
↔ / model-dependent |
G |
Induction of programmed cancer-cell death |
Demonstrated primarily using betanin or betalain-rich extracts in colorectal, breast, and lung cancer models. Human tumor exposure remains unverified. |
| 3 |
Cell-Cycle Regulation |
↑ arrest; ↓ proliferation |
↔ / model-dependent |
G |
Suppression of cancer-cell growth |
G2/M arrest and other cell-cycle effects depend on the cell line, preparation, and concentration. |
| 4 |
NF-κB / COX-2 / iNOS / Cytokines |
↓ inflammatory signaling |
↓ excessive inflammation (model-dependent) |
G |
Anti-inflammatory modulation |
Experimental reductions in TNF-α, IL-6, COX-2, and iNOS. Not established as an anticancer treatment mechanism in humans. |
| 5 |
Mitochondrial Membrane Potential / Apoptosis |
↑ mitochondrial dysfunction; ↑ apoptotic signaling |
↔ / model-dependent |
G |
Mitochondria-associated cancer-cell death |
Altered mitochondrial membrane potential and activation of intrinsic apoptosis observed in selected betanin-treated cancer models. MPTP opening is not established as a general beetroot mechanism. |
| 6 |
ROS and Oxidative Stress |
↑ or ↓ ROS (context-dependent) |
↓ oxidative damage |
R/G |
Redox modulation |
Betalains usually demonstrate antioxidant activity in nonmalignant systems; some cancer models show pro-oxidant cytotoxic responses. Direction cannot be generalized across preparations. |
| 7 |
Angiogenesis / CD31 |
↓ tumor-associated microvessels |
↔ / unestablished |
G |
Experimental suppression of tumor vascularization |
Reduced CD31-positive microvessels were observed in betanin-treated mouse lung tumor models. Not demonstrated clinically. |
| 8 |
PI3K / AKT / mTOR and MAPK |
↔ / model-dependent |
↔ / model-dependent |
G |
Possible growth and survival signaling modulation |
Reported across selected betalain models. Insufficient consistency to assign a universal activation or inhibition direction for whole beetroot. |
| 9 |
NRF2 / Antioxidant Defense |
↔ / context-dependent |
↑ antioxidant defenses (model-dependent) |
G |
Secondary cytoprotective signaling |
Potential contribution to protection against oxidative injury; direct NRF2-mediated cancer inhibition by dietary beetroot is not established. |
| 10 |
Clinical Translation Constraint |
Unverified therapeutic tumor exposure |
↑ systemic nitrate/NO metabolites; low intact betanin exposure |
R/G |
Limits extrapolation from preclinical studies |
Human oral dosing produces vascular nitrate responses but poor detectable intact betanin exposure. Anticancer experiments frequently use concentrated extracts or purified pigments at substantially higher exposure levels. No established cancer treatment dose or clinical efficacy. |
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr
|